Last reviewed · How we verify

NCT04368884

Assess the Seroconversion Status of Health Care Workers Suspected or Confirmed Cases of COVID-19 Patients

Status unknown Last updated 22 July 2020
What this trial tests

trial in Covid-19 in 1,000 participants. Status unknown.

Timeline
22 April 2020
Primary endpoint
30 June 2021
30 July 2021

Quick facts

Lead sponsorMax Healthcare Insititute Limited
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment1,000
Start date22 April 2020
Primary completion30 June 2021
Estimated completion30 July 2021
Sites1 location across India

Conditions studied

Sponsor

Max Healthcare Insititute Limited

Who can join

Adults 18 to 80, any sex, with Covid-19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A large number of Health Care Workers (HCWs) would be potentially getting exposed to COVID19. Some of them would be asymptomatic or may get subclinical symptoms. Our HCW would have higher exposure and possibly higher seroconversion either symptomatic or with clinical symptoms than the general population. This study is aimed to understand the rate of seroconversion states at different stages of exposure. It is crucial to collect baseline immune status and the early immunological changes that might occur in asymptomatic or symptomatic health care workers and to compare that with the suspected or confirmed cases by following them for six weeks.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Covid-19

Currently open trials in the same condition.

Other Max Healthcare Insititute Limited trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04368884.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing